Intraoperative Lidocaine Infusion and Surgery-induced Release of Pro-inflammatory Cytokines After Abdominal Surgery

Assiut University

Status: Enrolling

Conditions: Enhanced Recovery After Surgery

Treatments: Drug: lidocaine group; Drug: normal saline group

Study type: Interventional

Funder types: Other

Identifiers

NCT05541640

zzzz

Details and patient eligibility

About

Lidocaine is an amide local anaesthetic and an antiarrhythmic agent, first synthesized in 1942, and after approval for human use was launched in 1948 in Sweden The first observations of post operative analgesic effects of perioperative intravenous lidocaine (IVL) were initially proposed in 1951 subsequently many more enthusiastic reports followed. Postoperative formal clinical evaluations in the perioperative setting were conducted in the late 1950s where IV Lidocaine was demonstrated to have a postoperative analgesic effect without posing the risk of respiratory depression, reducing the occurrence of postoperative nausea and vomiting (PONV), and enhance post-surgical recovery. IV Lidocaine also potentiated the depth of anesthesia and led to a better tolerance of endotracheal intubation.Around 40% of patients experience a delay in resumption of normal bowel function after colorectal surgery. This delay leads to symptoms of nausea, vomiting, constipation, and abdominal distension, which then require unpleasant supportive interventions such as intravenous fluids and nasogastric tube insertion. There is no remedy to address this delay. ALLEGRO, "A placebo-controlled randomized trial of intravenous Lidocainein accelerating Gastrointestinal Recovery surgery," is the latest ongoing multicenter research study across the United Kingdom, investigating the use of intravenous lidocaine to improve recovery after colorectal surgery

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years and older.
• Both sexes, males and females
• Patients scheduled for elective intestinal surgery.
• Body mass index (BMI) 18-30 kg•m-2.
• ASA I - II.

Exclusion criteria

• Patient refusal
• Patients with preoperative gastrointestinal dysfunction.
• Patients with a history of drug abuse, or long-term opioid use.
• ASA III and VI
• Patients with a history of previous gastrointestinal surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

control group

Placebo Comparator group

Treatment:

Drug: normal saline group

lidocaine group

Active Comparator group

Treatment:

Drug: lidocaine group